A Study to Evaluate the Effect of Sarpogrelate on Blood Hyperviscosity

NCT03509922 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Peripheral Artery Disease, PAD

Interventions

DRUG: Anplag Tab. 100mg bid
DRUG: Anplag Tab. 100mg tid

Sponsor

Yuhan Corporation